Meta-Analysis
Copyright ©2013 Baishideng Publishing Group Co.
World J Meta-Anal. Nov 26, 2013; 1(3): 147-156
Published online Nov 26, 2013. doi: 10.13105/wjma.v1.i3.147
Table 1 The characteristics of the included studies in the meta-analysis and QUADAS scores
Ref.Country/regionMethylated genesNCRC
Adenoma
Normal
BlinddesignDetection methodQUADAS score
+-+-+-
Ahlquist et al[10]IrelandVimentin/NDRG4/BMP3/TFPI298264184541YesQuARTS11
Bosch et al[11], 2011NetherlandsPHACTR31854025613497UnclearqMSP10
GATA41602911316695
OSMR1852540415794
Ahlquist et al[12]IrelandPHACTR363921438514329264YesQuARTS11
Azuara et al[13]SpainRARB2/P16/MGMT/APC9825132020020YesMS-MCA10
RARB2851123731013
P1677921628013
MGMT80919334015
APC77919925015
Tang et al[14]ChinaSRRP2262142272934228YesMSP9
Baek et al[15]South KoreaVimentin/MGMT/MLH114945153121532YesMSP9
MLH11491842646037
Vimentin1492337844037
MGMT14931291933532
Li et al[16], 2009United StatesVimentin80913911236UnclearMethl-BEAMing5
Melotte et al[17], 2009NetherlandsNDRG41504233nrnr372YesqMSP11
Ausch et al[18], 2009United StatesIGTA437nrnr72622UnclearqMSP4
Hellebrekers et al[19], 2009NetherlandsGATA41504431nrnr966YesqMSP10
Mayor et al[20], 2009SpainEN160822nrnr129UnclearMS-MCA7
Kim et al[21], 2009United StatesOSMR/SFRP14212861105YesqMSP9
OSMR2013554214492
SFRP152119512015
Nagasaka et al[22], 2009JapanSFRP2253533118389104UnclearCOBRA10
RASSF225338467496107
Glöckner et al[23], 2009United StatesTFPI21294414719243YesqMSP12
Wang et al[24], 2008ChinaSFRP21336092113228YesMethyLight8
Oberwalder et al[25], 2008AustraliaSFRP219nrnr6706YesMethyLight9
Itzkowitz et al[26], 2008United StatesVimentin80913911236YesMSP13
Huang et al[27], 2007ChinaSFRP2/HPP1/MGMT97502156123YesMSP8
SFRP2974931110123
HPP1973715129024
MGMT972527615024
Itzkowitz et al[28], 2007United StatesVimentin/HLTF162319nrnr19103YesMSP13
HLTF1621525nrnr9113
Vimentin1622911nrnr16106
Abbaszadegan et al[29], 2007Hong Kongp1645520nrnr020UnclearMSP8
Zhang et al[30], 2007GermanySFRP14416470215YesMSP9
Leung et al[31], 2007Hong KongSFRP2/MGMT/MLH1/HLTF/ATM/APC75164187327YesMSP13
SFRP275614322228
MGMT75416322030
MLH175416322030
HLTF75515520129
ATM75515520030
APC75416421030
Petko et al[32], 2005United StatesMGMT/ CDKN2A/ MLH148nrnr1613712YesMSP9
CDKN2A48nrnr920316
MGMT48nrnr1415514
MLH148nrnr029217
Lenhard et al[33], 2005GermanyHIC171111549032YesMSP11
Chen et al[34], 2005United StatesVimentin26343516448111YesMSP11
Müller et al[35], 2004AustraliaSFRP2/ SRRP539203nrnr88UnclearMethyLight5
SRRP239194nrnr412
SRRP539185nrnr511
Xu et al[36], 2012ChinaSFRP29020101515129UnclearMSP5
Kang et al[37], 2011ChinaMGMT/ MAL/ CDKN2A119645177224UnclearMSP7
MAL11954151410125
CDKN2A11936331014026
MGMT1193831915125
Zhang et al[38], 2011ChinaVimentin/ OSMR/ TFPI2107528134426UnclearMSP9
Vimentin1073228512030
OSMR1074119710030
TFPI21074515116426
Fu et al[39], 2010ChinaVimentin2259nrnr08UnclearMSP5
Ling et al[40], 2009ChinaP1610847141611119UnclearMSP7
Cheng et al[41], 2007ChinaSFRP2974931110123UnclearMSP5
Zhao et al[42], 2009ChinaNDRG41146420nrnr327UnclearMSP6
Chang et al[43], 2010South KoreaIGTA4/SFRP2/P1686219187130YesMSP8
IGTA4861119421031
SFRP28618121114031
P16861218619130
Table 2 Methylation of pooled genes for the diagnosis of colorectal cancer
Wnt pathwayDNA damage repair pathwayOther pathwaysSE (95%CI)SP (95%CI)DOR (95%CI)AUC
Wnt pathwayDNA damage repair pathwayOther pathways73% (0.71-0.75)92% (90%-93%)30.86 (22.33-42.66)0.929
Wnt pathway--74% (70%-77%)93% (90%-95%)33.92 (17.73-64.90)0.932
-DNA damage repair pathway-42% (36%-47%)97% (94%-99%)12.87 (5.98-27.72)0.730
--Other pathways57% (55%-60%)94% (93%-95%)20.93 (15.56-28.15)0.921
SFRP2--79% (75%-82%)93% (90%-96%)47.57 (20.08-112.72)0.957
-MGMT-47% (40%-53%)95% (90%-98%)11.67 (5.10-26.67)0.709
-MLH-28% (18%-39%)100% (95%-100%)23.68 (3.02-185.44)0.500
--Vimentin48% (42%-54%)93% (90%-95%)14.95 (8.99-24.84)0.862
--OSMR47% (40%-54%)95% (91%-98%)14.66 (5.06-42.47)0.225
--P1650% (42%-58%)98% (92%-100%)24.39 (7.26-81.96)0.975
SFRP2MGMT-69% (66%-72%)94% (91%-96%)33.24 (16.76-65.93)0.946
SFRP2MLH-72% (68%-75%)94% (92%-96%)43.03 (20.15-91.87)0.953
SFRP2MLHVimentin64% (61%-67%)94% (92%-95%)27.11 (16.48-44.61)0.934
SFRP2MLHOSMR65% (62%-69%)95% (93%-96%)33.10 (17.12-63.98)0.951
SFRP2MLHP1668% (64%-71%)95% (93%-97%)38.86 (20.11-67.54)0.952
Table 3 Methylation of pooled genes for the diagnosis of colorectal adenomas
Wnt pathwayDNA damage repair pathwayOther pathwaysSE (95%CI)SP (95%CI)DOR (95%CI)AUC
Wnt pathwayDNA damage repair pathwayOther pathways51% (47%-54%)92% (90%-93%)12.61 (8.66-18.37)0.883
Wnt pathway--40% (35%-46%)95% (92%-97%)10.81 (6.43-18.16)0.932
-DNA damage repair pathway-21% (17%-27%)95% (91%-97%)4.23 (2.01-8.88)0.672
--Other pathways32% (28%-35%)94% (93%-95%)7.78 (5.48-11.05)0.873
SFRP2--43% (38%-49%)94% (91%-97%)11.06 (5.77-21.18)0.956
-MGMT-29% (22%-36%)93% (87%-96%)4.42 (2.18-8.95)0.614
-MLH-8% (4%-16%)98% (92%-100%)2.35 (0.14-40.83)-
--Vimentin23% (17%-31%)95% (92%-98%)8.30 (2.60-26.55)0.898
--OSMR25% (14%-39%)95% (91%-98%)5.20 (1.44-18.82)0.817
--P1633% (23%-44%)97% (89%-100%)13.27 (3.40-51.83)0.97
SFRP2MLH-34% (29%-39%)95% (92%-97%)9.62 (4.64-19.93)0.947
SFRP2MGMT-38% (33%-42%)94% (91%-96%)7.85 (4.79-12.87)0.753
SFRP2-OSMR41% (35%-46%)95% (92%-96%)9.25 (5.13-16.69)0.948
SFRP2-Vimentin36% (32%-41%)95% (93%-96%)9.88 (5.55-17.57)0.946
SFRP2-P1641% (36%-46%)95% (92%-97%)10.37 (6.21-17.31)0.948
SFRP2MGMTVimentin34% (30%-38%)94% (92%-96%)7.81 (4.96-12.29)0.804
SFRP2MGMTOSMR36% (32%-41%)94% (92%-96%)7.25 (4.61-11.39)0.775
SFRP2MGMTP1637% (33%-41%)94% (92%-96%)7.92 (5.14-12.21)0.772
SFRP2MLHVimentin31% (27%-35%)95% (93%-97%)8.99 (4.95-16.31)0.944
SFRP2MLHOSMR33% (29%-38%)95% (93%-97%)8.37 (4.50-15.59)0.941
SFRP2MLHP1634% (30%-38%)95% (93%-97%)9.98 (5.45-18.27)0.947
Table 4 Weighted meta-regression on the diagnostic accuracy of the gene methylation assays
CovariateCoefficientSEP valueRDOR95%CI
QUADAS score1-0.2590.4190.5410.77(0.33, 1.82)
Detection method20.1010.3770.7901.11(0.51, 2.40)
Blinded design3-0.1790.3810.6420.84(0.38, 1.82)
Methylated genes40.3020.3940.4491.35(0.60, 3.03)